The microRNA-200 (miR-200) family has emerged as a critical regulator in non-small-cell lung cancer (NSCLC), orchestrating a molecular switch centered on a bistable feedback loop with ZEB1/ZEB2 transcription factors that governs epithelial–mesenchymal plasticity, therapeutic resistance, and immune evasion [2,3]. Here, ZEB2 is linked to non-small cell lung carcinoma.